PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PETS | PETMED EXPRESS INC | 2025-12-02 08:23:23 | 1.77 | 0.03 | 1.72 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PETS | 0001040130 | PETMED EXPRESS INC | US7163821066 | 529900PGHW5ASJ1AZL48 | 650680967 | Nasdaq | 5912 | Retail-Drug Stores and Proprietary Stores | 0331 | FL | 420 SOUTH CONGRESS AVENUE | DELRAY BEACH | FL | 33445 | UNITED STATES | US | (561) 426-4444 | 420 SOUTH CONGRESS AVENUE, DELRAY BEACH, FL, 33445 | 420 SOUTH CONGRESS AVENUE, DELRAY BEACH, FL, 33445 | — | Online pharmacy | 1996 | Sandra Campos | — | https://1800petmeds.com | 74,900,000 | 20,656,822 | 21,015,559 | PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication. | 2025-11-27 20:00:00 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 74,900,000 | -134,300,000 | -64.1969 | 21,015,559 | 408,867 | 1.9841 |
| 2024 | 209,200,000 | -187,200,000 | -47.225 | 20,606,692 | -542,000 | -2.5628 |
| 2023 | 396,400,000 | -143,700,000 | -26.6062 | 21,148,692 | 160,455 | 0.7645 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christine Chambers | Chief Financial Officer | 2024 | 375,000 | 0 | 233,913 | 0 | 26,342 | 635,255 |
| Mathew N. Hulett | President, Chief Executive Officer | 2024 | 500,000 | 0 | 0 | 0 | 34,019 | 534,019 |
| Mathew N. Hulett | President, Chief Executive Officer | 2023 | 500,000 | 0 | 0 | 0 | 34,119 | 534,119 |
| Bruce S. Rosenbloom | Chief Financial Officer | 2023 | 274,523 | 0 | 0 | — | 306,378 | 580,901 |
| Christine Chambers | Chief Financial Officer | 2023 | 237,981 | 50,000 | 346,080 | 0 | 17,420 | 651,481 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 173 |
| 2024 | 287 |
| 2023 | 302 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 226,972,000 | 281,064,000 | 256,858,000 |
| Cost Of Revenue | 157,835,000 | 202,416,000 | 185,844,000 |
| Gross Profit | 69,137,000 | 78,648,000 | 71,014,000 |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 38,647,000 | 55,246,000 | 49,474,000 |
| Operating Expenses | 70,667,000 | 86,810,000 | 72,444,000 |
| Operating Income | -1,530,000 | -8,162,000 | -1,430,000 |
| Net Income | -6,271,000 | -7,464,000 | 233,000 |
| Earnings Per Share Basic | -0.3 | -0.37 | 0.01 |
| Earnings Per Share Diluted | -0.3 | -0.37 | 0.01 |
| Weighted Average Shares Outstanding Basic | 20,596,022 | 20,395,959 | 20,275,000 |
| Weighted Average Shares Outstanding Diluted | 20,596,022 | 20,395,959 | 20,339,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 54,720,000 | 55,296,000 | 104,086,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 2,317,000 | 3,283,000 | 1,740,000 |
| Inventories | 16,205,000 | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 78,871,000 | 93,648,000 | 131,451,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 28,859,000 | 26,657,000 | 26,178,000 |
| Other Assets Non Current | 375,000 | 375,000 | — |
| Total Assets Non Current | 69,829,000 | 76,236,000 | 32,666,000 |
| Total Assets | 148,700,000 | 169,884,000 | 164,117,000 |
| Accounts Payable | 23,564,000 | 37,024,000 | 25,208,000 |
| Deferred Revenue | 2,085,000 | 2,603,000 | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 80,000 | — | — |
| Total Liabilities Current | 62,768,000 | 72,158,000 | 36,497,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | 3,825,000 |
| Total Liabilities Non Current | 798,000 | 995,000 | 3,825,000 |
| Total Liabilities | 63,566,000 | 73,153,000 | 40,322,000 |
| Common Stock | 21,000 | 21,000 | 21,000 |
| Retained Earnings | 66,544,000 | 71,555,000 | 105,488,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 85,134,000 | 96,731,000 | 123,795,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 7,039,000 | 7,056,000 | 3,546,000 |
| Share Based Compensation Expense | -6,586,000 | 6,869,000 | 6,617,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -601,000 | 1,742,000 | 41,000 |
| Change In Inventories | -12,351,000 | 6,417,000 | -13,432,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -13,460,000 | 6,102,000 | -2,292,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 4,718,000 | 4,317,000 | 27,803,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 5,113,000 | 4,511,000 | 5,260,000 |
| Acquisition Of Business | 0 | 35,859,000 | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -5,113,000 | -40,670,000 | -10,260,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | 12,640,000 | 25,241,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -181,000 | -12,437,000 | -24,537,000 |
| Change In Cash | -576,000 | -48,790,000 | -6,994,000 |
| Cash At End Of Period | 54,720,000 | 55,296,000 | 104,086,000 |
| Income Taxes Paid | 525,000 | 130,000 | 4,312,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.3 | -0.37 | 0.01 |
| Price To Earnings Ratio | -13.9667 | -12.6486 | 1,624 |
| Earnings Growth Rate | -18.9189 | -3,800 | -99.0476 |
| Price Earnings To Growth Ratio | 0.7382 | 0.0033 | -16.3962 |
| Book Value Per Share | 4.1335 | 4.7427 | 6.1058 |
| Price To Book Ratio | 1.0137 | 0.9868 | 2.6598 |
| Ebitda | 1,293,000 | -278,000 | 8,091,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | 0.1324 | 0.0767 |
| Dividend Payout Ratio | — | -1.6935 | 108.3305 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 9,241,000 | 7,535,000 | 5,260,000 |
| Free Cash Flow | -4,523,000 | -3,218,000 | 22,543,000 |
| Return On Equity | -0.0737 | -0.0772 | 0.0019 |
| One Year Beta | 1.1525 | 0.9468 | 0.877 |
| Three Year Beta | 0.9418 | 0.7747 | 0.7805 |
| Five Year Beta | 0.8367 | 0.6835 | 0.6693 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| FULGONI GIAN | Director | 2025-10-30 | 33,846 | A | 158,356 |
| Batushansky Peter | Director | 2025-10-30 | 33,846 | A | 36,373 |
| Solivan Leah | Director | 2025-10-30 | 33,846 | A | 42,289 |
| Mennen Justin L. | Director | 2025-10-30 | 33,846 | A | 42,719 |
| LaCamp James | Director | 2025-10-30 | 34,866 | A | 34,866 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 2025-09-30 | 14,686 | 5,851 | 2.51 |
| CIBC Private Wealth Group LLC | 2025-09-30 | 75,300 | 30,000 | 2.51 |
| GOLDMAN SACHS GROUP INC | 2025-09-30 | 72,092 | 28,722 | 2.51 |
| Man Group plc | 2025-09-30 | 379,108 | 151,039 | 2.51 |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 2025-09-30 | 1,978,139 | 788,103 | 2.51 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Gabelli Innovations Trust | 2025-09-30 | Gabelli Pet Parents'(TM) Fund | PETZX | 5,000 | 12,550 | 0.3467 |
| Gabelli Innovations Trust | 2025-09-30 | Gabelli Pet Parents'(TM) Fund | PETZX | 37,500 | 103,288.32 | 2.8532 |
| GABELLI EQUITY SERIES FUNDS INC | 2025-09-30 | Class I | GACIX | 80,000 | 220,348.42 | 0.0119 |
| GABELLI EQUITY SERIES FUNDS INC | 2025-09-30 | CLASS C | GCCSX | 80,000 | 220,348.42 | 0.0119 |
| GABELLI EQUITY SERIES FUNDS INC | 2025-09-30 | CLASS AAA | GABSX | 80,000 | 220,348.42 | 0.0119 |